2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Sales - EUR | 157.352 | 108.626 | 85.399 | 80.268 | 81.535 | 79.741 | 107.847 | 185.079 | 34.103 | 52.822 |
Total Income - EUR | 155.996 | 103.533 | 85.480 | 80.830 | 82.832 | 82.383 | 107.903 | 185.168 | 34.404 | 52.978 |
Total Expenses - EUR | 104.410 | 63.240 | 46.997 | 35.802 | 55.751 | 49.870 | 35.087 | 58.140 | 21.926 | 25.865 |
Gross Profit/Loss - EUR | 51.586 | 40.292 | 38.483 | 45.028 | 27.082 | 32.513 | 72.817 | 127.028 | 12.478 | 27.114 |
Net Profit/Loss - EUR | 43.254 | 33.722 | 32.214 | 43.946 | 26.266 | 31.715 | 71.776 | 125.177 | 12.137 | 26.586 |
Employees | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Bioimpex Srl
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Fixed Assets | 351 | 330 | 5.794 | 4.911 | 4.050 | 3.215 | 2.413 | 8.006 | 6.000 | 3.957 |
Current Assets | 151.749 | 192.223 | 123.589 | 143.853 | 136.095 | 140.589 | 149.567 | 257.966 | 117.425 | 131.548 |
Inventories | 8.618 | 3.618 | 3.983 | 3.916 | 3.844 | 3.769 | 3.698 | 3.616 | 3.627 | 3.616 |
Receivables | 136.191 | 169.034 | 115.391 | 115.974 | 103.188 | 129.901 | 133.622 | 244.044 | 104.577 | 125.883 |
Cash | 6.940 | 19.571 | 4.214 | 23.964 | 29.063 | 6.919 | 12.248 | 10.306 | 9.221 | 2.049 |
Shareholders Funds | 146.262 | 181.153 | 117.245 | 131.390 | 112.946 | 120.736 | 138.761 | 260.867 | 118.528 | 128.274 |
Social Capital | 45 | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 |
Debts | 5.665 | 11.400 | 12.138 | 17.374 | 27.198 | 23.068 | 13.219 | 5.106 | 4.897 | 7.231 |
Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Exchange rate - RON | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 | 4.4821 |
Main CAEN | "128 - 128" | |||||||||
CAEN Financial Year |
129
|
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Comments - Bioimpex Srl